Pharma majors gear up to launch molnupiravir
2 years, 11 months ago

Pharma majors gear up to launch molnupiravir

The Hindu  

Cipla, Sun Pharma and Dr. Reddy’s Laboratories were among the clutch of pharma firms that on Tuesday said they will soon be launching molnupiravir capsules. Dr. Reddy’s said it would soon launch its molnupiravir 200mg capsules under the brand name Molflu in the country. Prasad said, “The approval to launch molnupiravir is an important development not only as a treatment option, but also for the collaborative manner in which Indian pharma companies came together.” Sun Pharmaceutical Industries said one of its wholly owned subsidiaries has received EUA from the DCGI to manufacture and market a generic version of MSD and Ridgeback’s molnupiravir under the brand name Molxvir. Another Hyderabad-based pharma group Hetero said it has received approval to manufacture and market molnupiravir capsules 200 mg.

India Launch Drug Dcgi Sun Pharma Hetero Molnupiravir Pharma Majors  brand  pharma  majors  molnupiravir  soon  manufacture  received  launch  treatment  india  gear  drug

History of this topic

Generic Drugmakers to Make Cheap Versions of Merck's Covid-19 Pill Molnupiravir for Poorer Nations
2 years, 11 months ago

Generic Drugmakers to Make Cheap Versions of Merck's Covid-19 Pill Molnupiravir for Poorer Nations

News 18  

A UN-backed agency has struck a deal for nearly 30 generic drugmakers to make low-cost versions of Merck & Co’s Covid-19 pill molnupiravir for poorer nations, widening access to a drug seen as a weapon in fighting the pandemic. A molnupiravir course of 40 pills for five days is expected to cost about $20 in poorer nations, an MPP official …

Natco, 9 others chosen to supply COVID-19 drug
2 years, 11 months ago

Natco, 9 others chosen to supply COVID-19 drug

The Hindu  

January 20, 2022 10:45 pm | Updated January 21, 2022 12:52 am IST - HYDERABAD United Nations-backed public health organisation Medicines Patent Pool has signed sublicence agreements with 10 generic drugmakers in India for the manufacturing of COVID-19 antiviral oral drug molnupiravir and supply in 105 low- and-middle-income countries. Natco, Strides, Biophore, SMS Pharmaceuticals, Laurus, Lupin, MSN, Arene Lifesciences, BDR …

Lupin launches antiviral medication Molnulup for COVID-19 treatment in India
2 years, 11 months ago

Lupin launches antiviral medication Molnulup for COVID-19 treatment in India

Firstpost  

Molnupiravir has been given emergency use authorisation by the DCGI for treatment of adult COVID-19 patients who have a high risk of progression of the disease, including hospitalisation. New Delhi: Drugmaker Lupin on Friday said it has launched antiviral medication Molnupiravir under the brand name Molnulup in the country for the treatment of COVID-19. Molnupiravir has been given emergency use …

Covid antiviral drug Molnupiravir has major safety concerns: ICMR chief
2 years, 11 months ago

Covid antiviral drug Molnupiravir has major safety concerns: ICMR chief

The Hindu  

ICMR Chief Dr. Balram Bhargava said on January 5 that Covid antiviral drug Molnupiravir has major safety concerns and has not been included in the national protocol for treatment of coronavirus. “Molnupiravir will now be manufactured in the country by 13 companies for restricted use under emergency situations for treatment of adult patients with COVID-19 and who have high risk …

Aurobindo Pharma launches COVID-19 drug Molnupiravir in India
2 years, 11 months ago

Aurobindo Pharma launches COVID-19 drug Molnupiravir in India

Deccan Chronicle  

Hyderabad: Aurobindo Pharma Limited has launched COVID-19 treatment drug Molnupiravir under brand name "Molnaflu" in India. Earlier last year, Aurobindo had signed a bi-lateral non-exclusive voluntary licensing agreement with Merck Sharpe Dohme, Singapore, a subsidiary of Merck & Co. to manufacture and supply Molnupiravir to over 100 low and middle-income countries, including India. K Nithyananda Reddy, Vice Chairman and Managing …

Molnupiravir, oral anti-Covid medicine, set for launch in India; to cost Rs 649 per strip
2 years, 11 months ago

Molnupiravir, oral anti-Covid medicine, set for launch in India; to cost Rs 649 per strip

India TV News  

Molnupiravir, the world’s first and only oral antiviral to be approved by the US FDA, UK MHRA and Indian CDSCO for treatment of COVID-19, is set for a launch. Last week, the Drugs Controller General of India, based on the review of clinical data of molnupiravir, approved molnupiravir for treatment of adult patients with Covid-19, with SpO2 > 93% and …

EXPLAINED: As Covid Antiviral Molnupiravir Launches In India, Here's All You Need To Know About The Pill
2 years, 11 months ago

EXPLAINED: As Covid Antiviral Molnupiravir Launches In India, Here's All You Need To Know About The Pill

News 18  

Days after it received an emergency use nod from the Indian drugs regulator, the antiviral molnupiravir has already hit the markets with more than a dozen Indian companies working on rolling out the pill by taking advantage of the patent waiver offered by its American makers for production in low- and middle-income countries. Molnupiravir has received an emergency nod in …

Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week
2 years, 11 months ago

Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week

News 18  

Mankind Pharma’s chairman has said the company’s will launch the cheapest Molnupiravir, the Covid-19 antiviral drug, at Rs 35 per capsule, the Economic Times said in a report. Molnupiravir, developed by MSD and Ridgeback Biotherapeutics, has been approved by the UK Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration for the treatment of mild-to-moderate Covid-19 …

Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know
2 years, 11 months ago

Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know

Firstpost  

Molnupiravir, developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US pharma giant Merck, was approved for emergency use in India on Tuesday The Drug Controller General of India had earlier this week approved Molnupiravir for restricted use in an emergency situation in India. Brinton Pharmaceuticals on Thursday said it will launch its generic version of anti-COVID-19 pill Molnupiravir …

Covid Pill Molnupiravir’s Treatment for 5 Days May Cost Rs 1,600-Rs 3,000
2 years, 11 months ago

Covid Pill Molnupiravir’s Treatment for 5 Days May Cost Rs 1,600-Rs 3,000

News 18  

The anti-viral Covid pill, Molnupiravir, may be priced Rs 40 to Rs 75 per tablet thus making the cost of the entire treatment around Rs 3,000 for five days, the head of Optimus Pharma, one of the 13 companies launching the drug in India, told News18. The recommended dose of Molnupiravir is 800 milligram twice a day for five days, …

Approved by India, Full Treatment of Anti-Viral Drug Molnupiravir May Cost Up to Rs 3,000: Report
2 years, 11 months ago

Approved by India, Full Treatment of Anti-Viral Drug Molnupiravir May Cost Up to Rs 3,000: Report

News 18  

Anti-viral drug Molnupiravir, which has got the green flag from the Drug Controller General of India for emergency use approval to treat Covid-19, is expected to cost between ₹2,000 and ₹3,000 for full treatment. Earlier, Merck had said it “plans to implement a tiered pricing approach based on World Bank country income criteria to reflect countries’ relative ability to finance …

Merck’s covid-19 pill backed by FDA advisers
3 years ago

Merck’s covid-19 pill backed by FDA advisers

Live Mint  

An outside panel of scientific advisers to the Food and Drug Administration narrowly recommended the agency authorize the experimental Covid-19 oral antiviral from Merck & Co. and partner Ridgeback Biotherapeutics LP. Several panel members who voted in favor of authorization said use of molnupiravir should be limited to unvaccinated people at high risk of Covid-19 complications, and that while more …

MSN Laboratories to start phase 3 clinical trial of covid-19 drug molnupiravir
3 years, 6 months ago

MSN Laboratories to start phase 3 clinical trial of covid-19 drug molnupiravir

Live Mint  

NEW DELHI: MSN Laboratories Pvt Ltd on Tuesday announced that it is starting phase 3 clinical trial of molnupiravir capsules for treatment of mild-to-moderate covid-19 in India. It will soon start clinical trials on more than 2,400 patients suffering from mild to moderate covid-19 at more than 40 sites across India. MSN’s phase 3 trial is the third firm to …

Discover Related